SCHEMBL4964136

SCHEMBL4964136

CC(C)(Cc1ccccc1)NC(=O)C1(Sc2ccccc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.49
ALDH1A1 P00352 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
LMNA P02545 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP1A2 P05177 1/20 0.41
RECQL P46063 1/20 0.41
OPRM1 P35372 2/20 0.41
OPRD1 P41143 2/20 0.41
OPRK1 P41145 2/20 0.41
MAPK1 P28482 1/20 0.40
ACACB O00763 2/20 0.36
MMP8 P22894 3/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
TSHR P16473 1/20 0.35
DPP4 P27487 2/20 0.35
MMP2 P08253 1/20 0.35
MMP12 P39900 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4964628 0.76 ALDH1A1 (0.37) ALDH1A1LMNAKMT2ATSHRNPC1
SCHEMBL7438262 0.75 CYP3A4 (0.51) CYP3A4ALDH1A1CYP2C9CYP2C19LMNA
SCHEMBL3135137 0.73 CYP3A4 (0.55) CYP3A4ALDH1A1CYP2C9CYP2C19LMNA
SCHEMBL5948337 0.72 CYP3A4 (0.67) CYP3A4ALDH1A1CYP2C9CYP2C19LMNA
SCHEMBL6406694 0.71 ALDH1A1 (0.48) CYP3A4ALDH1A1CYP2C9CYP2C19CYP2D6
SCHEMBL6514301 0.71 ALDH1A1 (0.65) CYP3A4ALDH1A1CYP2C9CYP2C19LMNA
SCHEMBL9719712 0.70 ALDH1A1 (0.42) ALDH1A1CYP2C19LMNAOPRM1MAPK1
SCHEMBL13813940 0.70 CYP3A4 (0.63) CYP3A4ALDH1A1CYP2C9CYP2C19LMNA
SCHEMBL4202728 0.68 KMT2A (0.44) CYP3A4ALDH1A1CYP2C19LMNAOPRM1
SCHEMBL1718875 0.68 CYP3A4 (0.61) CYP3A4ALDH1A1CYP2C9CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US claimed
EP-1773780-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP disclosed
EP-1773780-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-04-18 EP disclosed
WO-2006012227-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO disclosed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288338-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 CYP3A4 566/4885ALDH1A1 345/4885CYP2C9 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.